Skip to content

KLRS KLRS Stock-Based Comp

Stock-Based Comp at other companies

Eli Lilly logo
Eli LillyLLY
$161M+4.5%
Merck & Co. logo
Merck & Co.MRK
$185M-5.1%
Amgen logo
AmgenAMGN
$75M-11.8%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$257.4M+0.7%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$11.64M+48.8%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$15.58M+49.0%

Other financials

Income statement

See full
Operating income-$11.8M-14.3%
Net income-$10.9M-6.5%
EPS (diluted)-$0.46+81.7%

Balance sheet

See full
Cash & equivalents$34.4M-65.9%
Total debt$1.4M
Total equity$68.6M+7.3%
Total assets$109.8M+6.5%

Cash flow

See full
Operating cash flow-$11.6M-55.6%
CapEx$17.0K
Free cash flow-$7.1M

Valuation

See full
Market cap$96.83M+136%
Enterprise value$63.82M

Returns & leverage

See full
Return on equity-66.6%
Debt / equity
Current ratio12.2×-2.1×

Where this comes from

Reported directly by KLRS in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: KLRS’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about KLRS's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is KLRS's stock-based comp?
KLRS (KLRS) reported stock-based comp of $580K in Q1 2026.
How has KLRS's stock-based comp changed year-over-year?
KLRS's stock-based comp increased by 55.1% year-over-year, from $374K to $580K.
What is the long-term trend for KLRS's stock-based comp?
Over 3 years (2021 to 2025), KLRS's stock-based comp has grown at a -64.7% compound annual growth rate (CAGR), from $43.98M to $1.94M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.